Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Blueprint Medicines Corporation BPMC
$53.47
+$0.06 (0.11%)
На 18:00, 12 мая 2023
+75.80%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
3238628588.00000000
-
week52high
79.40
-
week52low
37.82
-
Revenue
204036000
-
P/E TTM
-6
-
Beta
0.71107200
-
EPS
-9.42000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 12:00
Описание компании
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Jefferies | Buy | Buy | 22 авг 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 18 авг 2022 г. |
| Stifel | Buy | Buy | 18 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 17 авг 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 03 авг 2022 г. |
| Berenberg | Buy | 14 сент 2022 г. | |
| Morgan Stanley | Equal-Weight | Equal-Weight | 09 сент 2022 г. |
| Oppenheimer | Outperform | Outperform | 07 сент 2022 г. |
| Wedbush | Outperform | Outperform | 02 ноя 2022 г. |
| Oppenheimer | Perform | Outperform | 02 ноя 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 02 ноя 2022 г. |
| Barclays | Equal-Weight | Equal-Weight | 02 ноя 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 04 ноя 2022 г. |
| Goldman Sachs | Buy | Buy | 03 ноя 2022 г. |
| Wells Fargo | Equal-Weight | Underweight | 03 янв 2023 г. |
| Needham | Buy | 14 дек 2022 г. | |
| Barclays | Equal-Weight | Equal-Weight | 12 дек 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 27 янв 2023 г. |
| Barclays | Equal-Weight | Equal-Weight | 23 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Tsai John | A | 7950 | 7950 | 06 янв 2023 г. |
| Tsai John | A | 3900 | 3900 | 06 янв 2023 г. |
| Albers Jeffrey W. | D | 20000 | 10000 | 05 дек 2022 г. |
| Albers Jeffrey W. | D | 95073 | 10000 | 05 дек 2022 г. |
| Albers Jeffrey W. | D | 183243 | 20000 | 05 дек 2022 г. |
| Albers Jeffrey W. | A | 203243 | 10000 | 05 дек 2022 г. |
| Albers Jeffrey W. | A | 193243 | 10000 | 05 дек 2022 г. |
| Haviland Kate | A | 92281 | 1100 | 03 ноя 2022 г. |
| Rossi Christina | D | 43435 | 533 | 03 ноя 2022 г. |
| Namouni Fouad | D | 52797 | 3477 | 04 окт 2022 г. |
Новостная лента
Blueprint Is Well-Positioned To Capitalize On ISM Market (Maintain 'Buy')
Seeking Alpha
09 мая 2023 г. в 02:28
Blueprint Medicines focuses on developing precision therapies for genomically defined cancers and blood disorders, with two approved drugs and multiple ongoing programs. The company's stock has risen by 25% since the previous analysis, supported by strong financials and promising Phase 2 trial results for avapritinib in treating ISM.
Blueprint's (BPMC) Q1 Earnings & Sales Top Estimates, View Up
Zacks Investment Research
05 мая 2023 г. в 08:23
Blueprint Medicines (BPMC) announces better-than-expected results for first-quarter 2023 as it beats estimates for both earnings and revenues. Stock surges 13% following the news.
Blueprint's (BPMC) Q4 Earnings & Sales Top Estimates, Stock Up
Zacks Investment Research
17 февр 2023 г. в 10:32
Blueprint Medicines (BPMC) announces better-than-expected financial performance in fourth-quarter and full-year 2022. Stock up in the aftermarket hours, following the news release.
Blueprint Medicines Corporation (BPMC) Q4 2022 Earnings Call Transcript
Seeking Alpha
16 февр 2023 г. в 14:27
Blueprint Medicines Corporation (NASDAQ:BPMC ) Q4 2022 Earnings Conference Call February 16, 2023 8:00 AM ET Company Participants Jenna Cohen - Senior Director and Head of Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Christy Rossi - Chief Operating Officer Mike Landsittel - Chief Financial Officer Fouad Namouni - President of Research and Development Becker Hewes - MD, Chief Medical Officer Conference Call Participants Dane Leone - Raymond James Ernie Rodriguez - Cowen and Co Brad Canino - Stifel Eun Yang - Jefferies Derek Archila - Wells Fargo Michael Ulz - Morgan Stanley Reni Benjamin - JMP Securities Joe Beatty - Baird Peter Lawson - Barclays David Lebowitz - Citi Zhi Shu - Berenberg Ami Fadia - Needham Matt Biegler - Oppenheimer Nicole Gabreski - Piper Sandler Operator Good morning, and welcome to the Blueprint Medicines Conference Call. At this time, all participants are in listen-only-mode.
Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
16 февр 2023 г. в 09:47
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 2.93% and 18.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?